Lakefront Biotherapeutics (LKFT) Income from Continuing Operations (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Income from Continuing Operations data on file, last reported at 16338926.29 in Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 16338926.29, up 109.93% year-over-year; the trailing twelve-month figure through Mar 2026 was 541135755.27 (up 378.01% YoY), and the FY2025 annual result was 371902590.6, up 27247.38% from the prior year.
• Income from Continuing Operations slipped to 16338926.29 in Q1 2026 per LKFT's latest filing, from 911626498.75 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 911626498.75 in Q4 2025 and troughed at 564265482.83 in Q3 2025.
• A 5-year average of 10473056.48 and a median of 13853030.97 in 2022 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations sank 1466.13% in 2022, then soared 4382.72% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 64575536.74 in 2022, then gained by 28.77% to 45996431.11 in 2023, then surged by 144.21% to 20336439.06 in 2024, then soared by 4382.72% to 911626498.75 in 2025, then plunged by 98.21% to 16338926.29 in 2026.
• Business Quant data shows LKFT's Income from Continuing Operations at 16338926.29 in Q1 2026, 911626498.75 in Q4 2025, and 564265482.83 in Q3 2025.